Intelligence / B2B SaaS / Acquisitions / Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc.
9 Oct 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 9 Oct 2026
- Ticker
- HEPA
- Role
- Completed an acquisition
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 2.01, 3.02, 5.02, 9.01
- Summary
- On October 6, 2026, the Company completed the acquisition of all of the issued and outstanding membership interests of GLS from the Sole Member pursuant to the Purchase Agreement. As a result of the Closing, GLS became a wholly owned subsidiary of the Company.
- Location
- Red Bank, NJ
- State
- New Jersey
- Country
- United States
- SEC CIK
- 1583771
- Reference
- 0001493152-26-046546
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Find the decision makers at Hepion Pharmaceuticals, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
Across AOS Research
Other records for Hepion Pharmaceuticals, Inc. in our registers.
More in Completed an acquisition
Acquisitions
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.